Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: A randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« Ultrasound pulses could replace daily injections for diabetics

Searchable Genome for Drug Development »

Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: A randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study

November 30, 2013 by 2012pharmaceutical

See on Scoop.it – Cardiovascular and vascular imaging

Journal of Cardiovascular Pharmacology

See on www.mdlinx.com

Posted in Uncategorized | Leave a Comment

Leave a ReplyCancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 9,319 other subscribers
Recent Posts
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: